A review on recent advances in cardiovascular pharmacotherapy: Emerging therapies, novel anticoagulants, and cardiometabolic innovations

Cardiovascular diseases continue to be the top cause of death and illness across the globe. Therefore, the development of new treatment options must continue. The last few years have seen positive development in the treatment of the heart and blood vessels with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), new oral anticoagulants (NOACs), and sodium-glucoside cotransporter-2 inhibitors (SGLT2), as well as new molecules. The purpose of this article is to look at the most recent occurrences in cardiovascular medicine and their possible effects in practice. Large-scale randomized controlled trials and modern medicine show, for example, that besides controlling blood sugar, GLP-1 RAs have a protective effect on the heart and blood vessels. Also, NOACs provide an effective, safer anticoagulation compared to traditional vitamin K antagonists. Newer treatments such as mavacamten, tirzepatide, evolocumab, and vutrisiran fulfill unaddressed clinical needs and represent advances in tailored therapies for patients with heart problems. There have also been various treatment combinations and polypills that have been shown to have a positive effect on patient compliance to treatment and positive outcomes. Broadly speaking, these advances have shown positive outcomes for patients and improved care in cardiovascular medicine. There also needs to be additional study on the integration of these therapies into cardiovascular care.